Back HCV Treatment

HCV Treatment

EASL 2014: Sofosbuvir Works Well Despite Multiple Negative Predictive Factors

Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having 4 or more negative predictive factors, however, raises the risk of post-treatment relapse, according to a report at the 49th EASL International Liver Congress held recently in London.alt

Read more:

AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence

A 3-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C virus (HCV) in a small Phase 2 study reported last week at the 49th EASL International Liver Congress (EASL 2014) in London.

alt

Read more:

EASL 2014: MK-5172 + MK-8742 Demonstrate Good Early Post-Treatment Response Rates

A combination of 2 direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for genotype 1 hepatitis C patients, including people with cirrhosis or HIV/HCV coinfection, according to a series of presentations last week at the 49th EASL International Liver Congress in London.

alt

Read more:

EASL 2014: Sofosbuvir + GS-5816 NS5A Inhibitor Is Effective Against HCV Genotypes 1-6

A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people with hepatitis C genotypes 1 through 6, according to Phase 2 results presented at the 49thEASL International Liver Congress last week in London.

alt

Read more:

EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cures 100% of Previously Untreated HCV Genotype 4

A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, as well as all treatment-experienced patients followed for 4 weeks post-treatment, Christophe Hézode of Hôpital Henri Mondor in Paris reported at the 49th EASL International Liver Congress last week in London.

alt

Read more: